20:35 , Jan 18, 2019 |  BC Week In Review  |  Financial News

INmuneBio sets IPO terms

INmuneBio Inc. (La Jolla, Calif.) amended its NASDAQ IPO and now plans to sell between 1 million and 2.5 million shares at $8. At the midpoint of 1.75 million shares, the company would raise $14...
04:50 , Nov 30, 2018 |  BC Innovations  |  Targets & Mechanisms

Revving up metabolism at ASH 2018

Cancer metabolism is a prominent theme at this year’s ASH meeting, with researchers broadening the tent from metabolic targets that drive hematologic malignancies to those that intersect with other hot topics, notably immuno-oncology and epigenetics....
21:10 , Jun 21, 2018 |  BC Innovations  |  Translation in Brief

Liver’s killer instinct

A study in Science suggests natural killer T cells residing in the liver uniquely position the organ to reap antitumor effects from antibiotic-mediated microbiome depletion, uncovering a novel link in the microbiome-cancer relationship that highlights...
22:45 , Jun 20, 2018 |  BC Extra  |  Company News

Management tracks: Sanofi, NantKwest

Sanofi (Euronext:SAN; NYSE:SNY) hired Jean-Baptiste Chasseloup de Chatillon as EVP and CFO, effective Oct. 1. He was CFO and EVP at automotive company PSA Group (Euronext:UG). Natural killer cell company NantKwest Inc. (NASDAQ:NK) said Chief...
19:13 , Jun 20, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer; melanoma Cell culture and mouse studies suggest adoptive transfer of IL-15-cultured T cells could help treat B7-H6 tumor cell ligand-positive cancers. CD8 + T cells derived from human donor blood and cultured for...
18:20 , Jun 13, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Liver cancer Mouse studies suggest primary bile acids or depletion of gut microbiota could help treat liver tumors by increasing hepatic natural killer T (NKT) cell infiltration. In mouse models of liver cancer and...
01:36 , Jun 8, 2018 |  BC Innovations  |  Tools & Techniques

NK cell check-in

Until recently, there’s been scarce overlap between the NK cell field and the world of checkpoint inhibitors, with the former focused on cell therapies to kill tumor cells directly and the latter on relieving immune...
21:06 , May 16, 2018 |  BC Extra  |  Preclinical News

Nanoparticle pretreatment could boost solid tumor CAR T therapy

Research from the University of Washington and the Fred Hutchinson Cancer Research Center suggests preconditioning cancer patients with immunomodulatory nanoparticles could increase the efficacy of CAR T therapies to treat solid tumors. The main hypothesis...
23:45 , Apr 20, 2018 |  BioCentury  |  Product Development

Lessons from the ECHO chamber

Lessons from the failure of ECHO-301 go beyond the prospects of combining IDO1 and PD-1 inhibition to treat cancer. The broader concern is for the gamut of Phase I/II trials testing PD-1 combinations, many of...
23:07 , Apr 16, 2018 |  BC Extra  |  Clinical News

Merck rises, BMS falls on PD-1 combo data for NSCLC

Merck & Co. Inc. (NYSE:MRK) and Bristol-Myers Squibb Co. (NYSE:BMY) both reported detailed data Monday from Phase III trials of their anti-PD-1 mAb combos to treat advanced non-small cell lung cancer in the first-line setting....